TCRR News and Press, TCR2 Therapeutics Inc. From 03/29/21

85,000 square foot state-of-the-art facility being built in Rockville, Maryland Accelerates TCR 2 ’s commercial-scale manufacturing timelines with production anticipated in 2023 Aaron Vernon hired as Vice President of Technical Operations CAMBRIDGE, Mass., March...

TCR2 Therapeutics (TCRR): Q4 GAAP EPS of -$0.55 beats by $0.02.Cash, cash equivalents, and investments of $228.0 million at the end of 2020 compared to $158.1 million as of December 31, 2019.Press Release For further details see: TCR2 Therapeutics EPS beats by $0.02

-  Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021 -  Preclinical data on autologous CD70 and allogeneic mesothelin TRuC data at AACR 2021 -  Raised gross proceeds of $140M in a follow-on offering in Januar...

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that three e-poster presentations featuring new clinical data...

CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will present an update on Company progress at...

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therape...

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR 2 ” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced th...

TCR2 Therapeutics (TCRR) has priced its public offering of ~4.6M common shares at $30.50/share, for expected gross proceeds of ~$140M.Underwriters' over-allotment is an additional ~688.5K shares. Net proceeds will be used to advance its clinical programs, for R&D activities, working capit...

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR 2 ” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced th...

TCR2 Therapeutics  ([[TCRR]] -0.4%) commences an underwritten public offering of $125M of shares of common stock.Underwriter's option to purchase up to an additional $18.75M shares.Actual size and terms yet to be finalised.Company intends to use the net proceeds to advance its ...